An Error Was Encountered

Error Number: 1054

Unknown column 'cache_on' in 'field list'

UPDATE `aff_pdf_cache` SET `cache` = 'a:10:{i:0;O:8:\"stdClass\":13:{s:2:\"id\";s:6:\"536484\";s:6:\"status\";s:8:\"verified\";s:11:\"author_name\";s:7:\"banktys\";s:9:\"author_id\";s:6:\"616748\";s:14:\"author_website\";s:0:\"\";s:5:\"title\";s:98:\"Testbank For The Principles of Learning and Behavior Active Learning Edition 6th Edition by Domjan\";s:11:\"description\";s:98:\"Testbank For The Principles of Learning and Behavior Active Learning Edition 6th Edition by Domjan\";s:5:\"thumb\";s:103:\"images/t/5365/the-principles-of-learning-and-behavior-active-learning-edition-6th-edition-by-domjan.jpg\";s:6:\"thumb2\";s:104:\"images/t2/5365/the-principles-of-learning-and-behavior-active-learning-edition-6th-edition-by-domjan.jpg\";s:9:\"permalink\";s:85:\"the-principles-of-learning-and-behavior-active-learning-edition-6th-edition-by-domjan\";s:5:\"pages\";s:1:\"2\";s:6:\"rating\";s:1:\"0\";s:5:\"voter\";s:1:\"0\";}i:1;O:8:\"stdClass\":13:{s:2:\"id\";s:5:\"34696\";s:6:\"status\";s:8:\"verified\";s:11:\"author_name\";s:13:\"gordonbarbier\";s:9:\"author_id\";s:4:\"5371\";s:14:\"author_website\";s:0:\"\";s:5:\"title\";s:72:\"Principles of Risk Management and Insurance Rejda 11th Edition Test Bank\";s:11:\"description\";s:73:\"Principles of Risk Management and Insurance Rejda 11th Edition Test Bank\n\";s:5:\"thumb\";s:89:\"images/t/347/principles-of-risk-management-and-insurance-rejda-11th-edition-test-bank.jpg\";s:6:\"thumb2\";s:90:\"images/t2/347/principles-of-risk-management-and-insurance-rejda-11th-edition-test-bank.jpg\";s:9:\"permalink\";s:72:\"principles-of-risk-management-and-insurance-rejda-11th-edition-test-bank\";s:5:\"pages\";s:2:\"48\";s:6:\"rating\";s:1:\"3\";s:5:\"voter\";s:1:\"7\";}i:2;O:8:\"stdClass\":13:{s:2:\"id\";s:5:\"58751\";s:6:\"status\";s:8:\"verified\";s:11:\"author_name\";s:8:\"bestsmtb\";s:9:\"author_id\";s:4:\"7439\";s:14:\"author_website\";s:0:\"\";s:5:\"title\";s:98:\" The Economics of Money, Banking, and Financial Markets, 3rd Editio Canadian, by Mishkin TEST BANK\";s:11:\"description\";s:348:\"\n The Economics of Money, Banking, and Financial Markets, 3rd Edition Canadian, by Mishkin TEST BANK \n---------------------------------------------------------\nMy email is: bestsmtb@gmail.com\nMy email is: bestsmtb@gmail.com\nMy website: www.bestsmtb.blogspot.com\nMy website: www.bestsmtb.blogspot.com\n-----------------------------------------------\n\";s:5:\"thumb\";s:110:\"images/t/588/the-economics-of-money-banking-and-financial-markets-3rd-editio-canadian-by-mishkin-test-bank.jpg\";s:6:\"thumb2\";s:111:\"images/t2/588/the-economics-of-money-banking-and-financial-markets-3rd-editio-canadian-by-mishkin-test-bank.jpg\";s:9:\"permalink\";s:93:\"the-economics-of-money-banking-and-financial-markets-3rd-editio-canadian-by-mishkin-test-bank\";s:5:\"pages\";s:2:\"34\";s:6:\"rating\";s:1:\"0\";s:5:\"voter\";s:1:\"0\";}i:3;O:8:\"stdClass\":13:{s:2:\"id\";s:6:\"112061\";s:6:\"status\";s:8:\"verified\";s:11:\"author_name\";s:10:\"cyberlenin\";s:9:\"author_id\";s:5:\"21870\";s:14:\"author_website\";s:0:\"\";s:5:\"title\";s:78:\"The Economics of Money, Banking and Financial Markets, Ninth Edition test bank\";s:11:\"description\";s:98:\"Testbank for The Economics of Money, Banking and Financial Markets, Ninth Edition. Hope you enjoy!\";s:5:\"thumb\";s:94:\"images/t/1121/the-economics-of-money-banking-and-financial-markets-ninth-edition-test-bank.jpg\";s:6:\"thumb2\";s:95:\"images/t2/1121/the-economics-of-money-banking-and-financial-markets-ninth-edition-test-bank.jpg\";s:9:\"permalink\";s:76:\"the-economics-of-money-banking-and-financial-markets-ninth-edition-test-bank\";s:5:\"pages\";s:3:\"650\";s:6:\"rating\";s:1:\"5\";s:5:\"voter\";s:1:\"5\";}i:4;O:8:\"stdClass\":13:{s:2:\"id\";s:6:\"536450\";s:6:\"status\";s:8:\"verified\";s:11:\"author_name\";s:7:\"banktys\";s:9:\"author_id\";s:6:\"616748\";s:14:\"author_website\";s:0:\"\";s:5:\"title\";s:97:\"Testbank For The Economics of Money Banking and Financial Markets 4th Canadian Edition by Mishkin\";s:11:\"description\";s:97:\"Testbank For The Economics of Money Banking and Financial Markets 4th Canadian Edition by Mishkin\";s:5:\"thumb\";s:102:\"images/t/5365/the-economics-of-money-banking-and-financial-markets-4th-canadian-edition-by-mishkin.jpg\";s:6:\"thumb2\";s:103:\"images/t2/5365/the-economics-of-money-banking-and-financial-markets-4th-canadian-edition-by-mishkin.jpg\";s:9:\"permalink\";s:84:\"the-economics-of-money-banking-and-financial-markets-4th-canadian-edition-by-mishkin\";s:5:\"pages\";s:1:\"2\";s:6:\"rating\";s:1:\"0\";s:5:\"voter\";s:1:\"0\";}i:5;O:8:\"stdClass\":13:{s:2:\"id\";s:6:\"536451\";s:6:\"status\";s:8:\"verified\";s:11:\"author_name\";s:7:\"banktys\";s:9:\"author_id\";s:6:\"616748\";s:14:\"author_website\";s:0:\"\";s:5:\"title\";s:88:\"Testbank For The Economics of Money Banking and Financial Markets 9th Edition by Mishkin\";s:11:\"description\";s:88:\"Testbank For The Economics of Money Banking and Financial Markets 9th Edition by Mishkin\";s:5:\"thumb\";s:93:\"images/t/5365/the-economics-of-money-banking-and-financial-markets-9th-edition-by-mishkin.jpg\";s:6:\"thumb2\";s:94:\"images/t2/5365/the-economics-of-money-banking-and-financial-markets-9th-edition-by-mishkin.jpg\";s:9:\"permalink\";s:75:\"the-economics-of-money-banking-and-financial-markets-9th-edition-by-mishkin\";s:5:\"pages\";s:1:\"2\";s:6:\"rating\";s:1:\"0\";s:5:\"voter\";s:1:\"0\";}i:6;O:8:\"stdClass\":13:{s:2:\"id\";s:4:\"2983\";s:6:\"status\";s:8:\"verified\";s:11:\"author_name\";s:6:\"shinta\";s:9:\"author_id\";s:3:\"377\";s:14:\"author_website\";s:0:\"\";s:5:\"title\";s:125:\"The Mutagenic Activity of Chitosan and its Effect on the Growth of Trichoderma harzianum and Fusarium oxysporum F. Sp. Sesami\";s:11:\"description\";s:999:\"Five concentrations of chitosan; 0.38, 0.75, 1.50, 3.00 and 4.50 mg/ml were used to study its
\neffect on the growth of Fusarium oxysporum f sp. Sesami and Trichoderma harzianum. Chitosan inhibited
\nthe growth of Fusarium increasingly with the doses; 0.38, 0.75and 1.50 mg/ml, while no growth was
\nobtained when the two concentrations; 3.00and 4.50 mg/ml were used. In case of Trichoderma, in addition
\nto growth inhibition with chitosan treatment, two doses; 3.00 and 4.50 mg/ml resulted in changing the
\ngrowth color from green to yellow. It was found that chitosan treatment of Trichoderma with the two
\ndoses; 3.00 and 4.50 mg/ml has affected the fungus genetically. The induced mutants were isolated and
\ncharacterized. Chitosan Addition to the media enhanced the antagonistic properties of Trichoderma against
\nFusarium. Protein fingerprinting and Statistical analysis of the obtained data for the chitosan concentrations
\nand its control were done.\";s:5:\"thumb\";s:139:\"images/t/30/the-mutagenic-activity-of-chitosan-and-its-effect-on-the-growth-of-trichoderma-harzianum-and-fusarium-oxysporum-f-sp-sesami.jpg\";s:6:\"thumb2\";s:140:\"images/t2/30/the-mutagenic-activity-of-chitosan-and-its-effect-on-the-growth-of-trichoderma-harzianum-and-fusarium-oxysporum-f-sp-sesami.jpg\";s:9:\"permalink\";s:123:\"the-mutagenic-activity-of-chitosan-and-its-effect-on-the-growth-of-trichoderma-harzianum-and-fusarium-oxysporum-f-sp-sesami\";s:5:\"pages\";s:1:\"6\";s:6:\"rating\";s:7:\"3.16667\";s:5:\"voter\";s:1:\"6\";}i:7;O:8:\"stdClass\":13:{s:2:\"id\";s:6:\"134441\";s:6:\"status\";s:8:\"verified\";s:11:\"author_name\";s:12:\"davidross759\";s:9:\"author_id\";s:5:\"11679\";s:14:\"author_website\";s:0:\"\";s:5:\"title\";s:155:\"How to Create, Configure, and Manage a Design Inputs - Design Outputs Traceability Matrix utilizing the principles of Lean Documents and Lean Configuration\";s:11:\"description\";s:460:\"Design Inputs, Design Outputs, and Traceability matrices present a\nchallenge to almost all industries that apply design controls.\nTypically, these cause the creation and maintenance of duplicate\ninformation across various documents - a major source of errors. This\nwebinar applies the Theory of Lean Documents and the\ncorresponding Theory of Lean Configuration to avoiding these errors,\nwhile presenting a fresh new approach to these key and related\ndocuments.\";s:5:\"thumb\";s:117:\"images/t/1345/how-to-create-configure-and-manage-a-design-inputs-design-outputs-traceability-matrix-utilizing-the.jpg\";s:6:\"thumb2\";s:118:\"images/t2/1345/how-to-create-configure-and-manage-a-design-inputs-design-outputs-traceability-matrix-utilizing-the.jpg\";s:9:\"permalink\";s:99:\"how-to-create-configure-and-manage-a-design-inputs-design-outputs-traceability-matrix-utilizing-the\";s:5:\"pages\";s:1:\"2\";s:6:\"rating\";s:1:\"0\";s:5:\"voter\";s:1:\"0\";}i:8;O:8:\"stdClass\":13:{s:2:\"id\";s:5:\"13371\";s:6:\"status\";s:8:\"verified\";s:11:\"author_name\";s:7:\"samanta\";s:9:\"author_id\";s:4:\"1916\";s:14:\"author_website\";s:0:\"\";s:5:\"title\";s:151:\"Memorandum of Understanding Between The Office of Regulatory Affairs and The Center for Drug Evaluation and Research on the Pharmaceutical Inspectorate\";s:11:\"description\";s:954:\"FDA oversees the quality of drug products using a two-pronged approach involving review of infonnation submitted in applications as well as inspection of manufacturing facilities for confonnance to requirements for current Good Manufacturing Practices (cGMP). These two programs have served the consumer well by helping to ensure the quality of drug products available in the U.S. Now, as we approach the 25th anniversary of the last major revision to the drug cGMP regulations, it is time to step back and evaluate the currency of these programs and implement new ones, as appropriate, so that our resources are used most effectively and efficiently to address the most significant health risks. To this end, the Office of Regulatory Affairs and the Center for Drug Evaluation and Research have agreed to develop a Pharmaceutical Inspectorate (PI) of highly trained investigators whose primary responsibility will be conducting drug quality inspections.\";s:5:\"thumb\";s:117:\"images/t/134/memorandum-of-understanding-between-the-office-of-regulatory-affairs-and-the-center-for-drug-evaluat.jpg\";s:6:\"thumb2\";s:118:\"images/t2/134/memorandum-of-understanding-between-the-office-of-regulatory-affairs-and-the-center-for-drug-evaluat.jpg\";s:9:\"permalink\";s:100:\"memorandum-of-understanding-between-the-office-of-regulatory-affairs-and-the-center-for-drug-evaluat\";s:5:\"pages\";s:1:\"4\";s:6:\"rating\";s:1:\"0\";s:5:\"voter\";s:1:\"0\";}i:9;O:8:\"stdClass\":13:{s:2:\"id\";s:5:\"13374\";s:6:\"status\";s:8:\"verified\";s:11:\"author_name\";s:7:\"samanta\";s:9:\"author_id\";s:4:\"1916\";s:14:\"author_website\";s:0:\"\";s:5:\"title\";s:150:\"MEMORANDUM OF AGREEMENT BETWEEN THE OFFICE OF NEW DRUGS AND THE OFFICE OF SURVEILLANCE AND EPIDEMIOLOGY IN THE CENTER FOR DRUG EVALUATION AND RESEARCH\";s:11:\"description\";s:338:\"This document renews an agreement between the Office of New Drugs (OND) and the Office of Surveillance and Epidemiology (OSE) in the Center for Drug Evaluation and Research (CDER) of the Food and Drug Administration (FDA) on the management of significant safety issues associated with pending drug applications and approved drug products.\";s:5:\"thumb\";s:117:\"images/t/134/memorandum-of-agreement-between-the-office-of-new-drugs-and-the-office-of-surveillance-and-epidemiol.jpg\";s:6:\"thumb2\";s:118:\"images/t2/134/memorandum-of-agreement-between-the-office-of-new-drugs-and-the-office-of-surveillance-and-epidemiol.jpg\";s:9:\"permalink\";s:100:\"memorandum-of-agreement-between-the-office-of-new-drugs-and-the-office-of-surveillance-and-epidemiol\";s:5:\"pages\";s:1:\"7\";s:6:\"rating\";s:1:\"4\";s:5:\"voter\";s:1:\"2\";}}', `cache_on` = '2015-02-27 17:43:12' WHERE `aff_id` = '80062'